Skip to main content
. 2020 May 28;10(3):317–325. doi: 10.1002/cpdd.816

Figure 3.

Figure 3

Development of (A) HAHAs and (B) Nabs in Chinese healthy male subjects after a single 40‐mg subcutaneous injection of HS016 or adalimumab on days 14, 42, and 70 between the 2 groups (safety population). HAHA indicates human antihuman antibody; NAb, neutralizing antibody.